Association of Tamoxifen and Uterine Sarcoma
- 1 June 2002
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (11), 2758-2760
- https://doi.org/10.1200/jco.2002.20.11.2758
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Risk of Endometrial Cancer Following Estrogen Replacement With and Without ProgestinsJNCI Journal of the National Cancer Institute, 1999
- Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trialThe Lancet, 1999
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Evidence for a Common Etiology for Endometrial Carcinomas and Malignant Mixed Mullerian TumorsGynecologic Oncology, 1998
- Hormone replacement therapy and endometrial cancer risk: A meta-analysisObstetrics & Gynecology, 1995
- Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 *JNCI Journal of the National Cancer Institute, 1994
- Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsivenessThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Uterine sarcoma: Steroid receptors and response to hormonal therapyGynecologic Oncology, 1990
- Role of prolonged excessive estrogen stimulation in the pathogenesis of endometrial sarcomas: Two cases and a review of the literatureGynecologic Oncology, 1990
- Endometrial “sarcomas” complicating ovarian thecoma, polycystic ovarian disease and estrogen therapyGynecologic Oncology, 1985